Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06464055Phase 1Recruiting

A Study of GQ1010 in Subjects With Advanced Solid Tumors

Role: lead

NCT05575804Phase 1Recruiting

GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

Role: collaborator

NCT04450732Phase 1Unknown

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Role: lead

NCT06154343Phase 1Unknown

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Role: lead

All 4 trials loaded